- Home
- MBIN vs NVCR Comparison
MBIN vs NVCR Comparison
Compare MBIN & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBIN
- NVCR
- Stock Information
- Founded
- MBIN 1990
- NVCR 2000
- Country
- MBIN United States
- NVCR Switzerland
- Employees
- MBIN N/A
- NVCR N/A
- Industry
- MBIN Major Banks
- NVCR Medical/Dental Instruments
- Sector
- MBIN Finance
- NVCR Health Care
- Exchange
- MBIN Nasdaq
- NVCR Nasdaq
- Market Cap
- MBIN 1.5B
- NVCR 1.4B
- IPO Year
- MBIN 2017
- NVCR 2015
- Fundamental
- Price
- MBIN $32.30
- NVCR $12.28
- Analyst Decision
- MBIN Buy
- NVCR Buy
- Analyst Count
- MBIN 3
- NVCR 7
- Target Price
- MBIN $38.33
- NVCR $28.79
- AVG Volume (30 Days)
- MBIN 193.1K
- NVCR 1.3M
- Earning Date
- MBIN 10-27-2025
- NVCR 10-29-2025
- Dividend Yield
- MBIN 1.23%
- NVCR N/A
- EPS Growth
- MBIN N/A
- NVCR N/A
- EPS
- MBIN 4.55
- NVCR N/A
- Revenue
- MBIN $598,079,000.00
- NVCR $630,160,000.00
- Revenue This Year
- MBIN $4.09
- NVCR $6.68
- Revenue Next Year
- MBIN $7.88
- NVCR $7.01
- P/E Ratio
- MBIN $7.18
- NVCR N/A
- Revenue Growth
- MBIN N/A
- NVCR 14.58
- 52 Week Low
- MBIN $27.25
- NVCR $10.87
- 52 Week High
- MBIN $47.42
- NVCR $34.13
- Technical
- Relative Strength Index (RSI)
- MBIN 49.32
- NVCR 48.20
- Support Level
- MBIN $31.25
- NVCR $11.98
- Resistance Level
- MBIN $32.85
- NVCR $12.83
- Average True Range (ATR)
- MBIN 0.90
- NVCR 0.54
- MACD
- MBIN -0.00
- NVCR 0.13
- Stochastic Oscillator
- MBIN 46.15
- NVCR 31.86
About MBIN Merchants Bancorp
Merchants Bancorp is a United States based bank holding company. It operates multiple lines of business focusing on FHA (Federal Housing Administration) multi-family housing and healthcare facility financing and servicing, retail and correspondent residential mortgage banking, and traditional community banking. The business segments of the company are: Multi-family Mortgage Banking which originates and services government-sponsored mortgages for multi-family and healthcare facilities; Mortgage Warehousing segment which funds agency-eligible residential loans as well as commercial loans to nondepository financial institutions; and the Banking segment, which generates maximum revenue, and provides various financial products and services to consumers and businesses.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.